Kyowa Kirin Reports the Availability of Nourianz (Istradefylline) to Treat Parkinson’s Disease “Off” Episodes in the US

 Kyowa Kirin Reports the Availability of Nourianz (Istradefylline) to Treat Parkinson’s Disease “Off” Episodes in the US

Kyowa Kirin Reports the Availability of Nourianz (Istradefylline) to Treat Parkinson’s Disease “Off” Episodes in the US

Shots:

  • The Nourianz is now available in the US as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease experiencing motor fluctuations, re-emerge between treatment dose known as “off” episodes
  • The FDA’s approval of Nourianz is based clinical study assessing Nourianz vs PBO as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing “off” episodes, associated with a decrease in “off” time and an increase in “on” time without troublesome dyskinesia
  • Nourianz is an adenosine receptor antagonist, available in 20/40mg tablets and is the only therapy for PD that targets adenosine A2A receptor

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Pharmaceutical Technology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post